Results 231 to 240 of about 1,770,050 (315)

Identification of a type 1 diabetes-associated T cell receptor repertoire signature from the human peripheral blood. [PDF]

Sci Adv
Rawat P, Shapiro MR, Peters LD, Widrich M, Mayer-Blackwell K, Motwani K, Pavlović M, Al Hajj G, Posgai AL, Kanduri C, Isacchini G, Chernigovskaya M, Scheffer L, Motwani K, Balzano-Nogueira LO, Pettenger-Willey CM, Valkiers S, Jacobsen LM, Haller MJ, Schatz DA, Wasserfall CH, Emerson RO, Fiore-Gartland AJ, Atkinson MA, Klambauer G, Sandve GK, Greiff V, Brusko TM.   +27 more
europepmc   +1 more source

Weakening the nuclear envelope: Lamin B receptor in melanoma metastasis

Molecular Oncology, EarlyView.
LBR‐driven nuclear fragility supports melanoma invasion. A: Melanocyte presents low LBR (Lamin B Receptor) levels, maintaining nuclear integrity and lamina‐chromatin tethering. B: During malignant progression, upregulation of LBR clusters at the INM (Inner Nuclear Membrane) during confined migration causes local lamina weakening and cholesterol ...
Francesca Lorenzini, Maria Caterina Mione   +1 more
wiley   +1 more source

LCPBert: ProtBERT-based early-stage lung cancer prediction from T cell receptor beta sequences. [PDF]

iScience
Yang X, Zhou Y, Zhang Z, Luo H, Huang J.
europepmc   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia. [PDF]

Leukemia
Struckman NE, Koutsoumpli G, de Jong RCM, van der Lee DI, Remst DFG, Smith SI, Honders MW, Hagedoorn RS, de Ru AH, Matsuda M, Ishikawa F, Tak T, Valk PJM, Heemskerk MHM, van Veelen PA, Falkenburg JHF, Griffioen M.   +16 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

TRAIT: A Comprehensive Database for T-cell Receptor-antigen Interactions. [PDF]

Genomics Proteomics Bioinformatics
Wei M, Wu J, Bai S, Zhou Y, Chen Y, Zhang X, Zhao W, Chi Y, Pan G, Zhu F, Chen S, Zhou Z.   +11 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

ALIGaToR: a tool for the automated annotation of immunoglobulin and T cell receptor genomic loci. [PDF]

Oxf Open Immunol
Schramm CA, Olubo S, Douek DC.
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source